HomeCompareCAMRF vs EQR

CAMRF vs EQR: Dividend Comparison 2026

CAMRF yields 3.64% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $15.2K in total portfolio value
10 years
CAMRF
CAMRF
● Live price
3.64%
Share price
$55.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$459.40
Full CAMRF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — CAMRF vs EQR

📍 EQR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCAMRFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CAMRF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CAMRF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CAMRF
Annual income on $10K today (after 15% tax)
$309.09/yr
After 10yr DRIP, annual income (after tax)
$390.49/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, EQR beats the other by $2,856.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CAMRF + EQR for your $10,000?

CAMRF: 50%EQR: 50%
100% EQR50/50100% CAMRF
Portfolio after 10yr
$32.9K
Annual income
$2,139.50/yr
Blended yield
6.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

CAMRF
No analyst data
Altman Z
39.4
Piotroski
5/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CAMRF buys
0
EQR buys
0
No recent congressional trades found for CAMRF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCAMRFEQR
Forward yield3.64%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$25.3K$40.5K
Annual income after 10y$459.40$3,819.61
Total dividends collected$4.1K$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CAMRF vs EQR ($10,000, DRIP)

YearCAMRF PortfolioCAMRF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$11,064$363.64$11,248$547.57$184.00EQR
2$12,214$375.99$12,701$666.53$487.00EQR
3$13,457$387.94$14,405$814.59$948.00EQR
4$14,798$399.45$16,413$999.84$1.6KEQR
5$16,245$410.53$18,795$1,232.92$2.5KEQR
6$17,803$421.18$21,639$1,527.95$3.8KEQR
7$19,481$431.38$25,057$1,903.80$5.6KEQR
8$21,286$441.15$29,197$2,385.87$7.9KEQR
9$23,226$450.49$34,250$3,008.70$11.0KEQR
10$25,311$459.40$40,467$3,819.61$15.2KEQR

CAMRF vs EQR: Complete Analysis 2026

CAMRFStock

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.

Full CAMRF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this CAMRF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CAMRF vs SCHDCAMRF vs JEPICAMRF vs OCAMRF vs KOCAMRF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.